Chemical Testing Alone Cannot Anticipate the Potency of Full Spectrum Products
Other than Cannabinoid and terpene chemical compositional analysis and inferences of
potency therefrom, there has been little to no effort in the industry to validate products for
their actual biological potency using biomarkers within the endocannabinoid system. For the
non-psychotropic cannabinoids and terpenes, percent composition cannot predict how the
human endocannabinoid system will respond to individual purified Cannabinoids and
certainly cannot predict how multiple agonist and antagonist compounds within broad or full
spectrum products might affect patients. The industry needs to adopt the standards
comparable to how drug potency is measured and expressed throughout the pharmaceutical
industry, namely, units of activity per drug concentration (i.e. biological potency) as well as
chemical composition. CannaMetrix addresses this unmet need through proprietary human
cell-based potency testing that will establish a new high bar for the industry in Cannabis
products development and product validation.

CannaMetrix

Org chart

Teams

Offices

CannaMetrix

Org chart

Teams

Offices

Related companies